Navigation Links
Research shows biopsy of recurrent breast cancer can alter treatment
Date:3/18/2009

(Toronto March 18, 2009) For women with recurrent breast cancer, the treatment the doctor chooses is usually based on the properties of their original breast cancer. A group from Toronto has recently completed the world's first study that compared original breast cancer tumors with a biopsy of suspected tumors that recurred elsewhere in the body.

Researchers found that the biopsy resulted in 20% of the women having a significant change in their treatment. In some cases, this was a change in drug treatment and in others, the biopsy showed the woman did not actually have an advanced cancer, but a benign condition.

"The results show that cancers may change over time and not respond to treatment that was appropriate for the original cancer," says principal investigator Dr. Mark Clemons, a medical oncologist specializing in breast cancer in the Princess Margaret Hospital Cancer Program, University Health Network (UHN).

"These early findings are leading us in a new direction as we understand more about why some women don't respond to treatment. This knowledge will help us in our quest to always deliver the right treatment, to the right patient, at the right time."

The findings are published online today in the Annals of Oncology, Oxford University Press (Doi:10.1093/annonc/mdp028).

Dr. Clemons's study -- funded by a $100,000 research grant from the Canadian Breast Cancer Foundation - Ontario Region -- evaluated 29 biopsies of accessible, recurrent tumors taken from women whose breast cancer had spread to bone, skin, lymph nodes, lung or liver.

Pathologists compared the results of the original cancer with the results of the new biopsy by analyzing the predictive markers that influence breast cancer tumor growth estrogen, progesterone and Her2 status. The presence, absence and/or combinations of these markers become the map oncologists use to determine the most effective treatment for each patient.<
'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.on.ca
416-946-2846
University Health Network
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Georgia State/Georgia Tech Center for Advanced Brain Imaging to expand brain, mind research
2. Conflicts of interest in clinical research
3. Stimulus Spending Targets Modernization of the Nation's Research Infrastructure
4. Researchers Use Gene to End High Blood Sugar in Mice
5. Major Asthma Research Discovery Could Lead to New Drugs
6. Penn researchers identify new protein important in breast cancer genes role in DNA repair
7. New research suggests common anti-seizure medications may increase risk of cardiovascular problems
8. Researcher wins $2.6 million grant for depression care study
9. Frost and Sullivan Picks Epinex for Diabetes Research Award
10. Foundation for Biomedical Research Releases Groundbreaking PSA
11. Fish health claims may cause more environmental harm than good: UBC-St. Michaels researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/21/2014)... 2014 AngelWeddingDress.com’s new collection of 2015 ... total of 1,000 new designs in this collection, and ... 2015. , AngelWeddingDress.com promises to provide the ... wardrobe essentials while many fashion trends come and go. ... service team at AngelWeddingDress.com is ready to assist. ...
(Date:12/21/2014)... AlignLife of Norton Shores is ... the same time helping people get their health back. ... committed to serving those persons in Muskegon County who are ... the quality of life. Dr. Michael Rykse wanted to do ... local community and he knew he found that when he ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Theme ... announced a new intro plugin for Final Cut Pro ... pictures, videos, logos, and more with absolute ease.” Said ... our users the tools needed to easily animate their ... Final Cut Pro X users to animate pictures, videos, ...
(Date:12/20/2014)... BambooIndustry.com is a professional company offering ... has recently shown its new engineered bamboo flooring collection, ... flooring models. , BambooIndustry.com’s customers come from many countries ... According to the CEO of the company, the global ... the past few years, and the demand for eco-friendly ...
(Date:12/20/2014)... Dress company LunaDress has recently announced its 2015 ... offering big discounts on all of its special occasion dresses ... own a perfect wedding gown. If you have no idea ... to LunaDress. Many different wedding dress styles and our dress ... and enjoy the current special offer, up to 80% off," ...
Breaking Medicine News(10 mins):Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2
... New MRI Systems Set Trends Again: MAGNETOM Verio Brings ... Ever Before and MAGNETOM Essenza ... Price, MALVERN, Pa., Nov. 20 Siemens Medical,Solutions ... to,increased access to essential imaging services with the introduction ...
... save children,s lives runs through December 8 in all 6,200 ... ... be,participating in the fourth year of the St. Jude Children,s Research,Hospital(R) ... December 8. As part of this national,campaign, CVS/pharmacy has joined with ...
... Orchid Cellmark Inc.,(Nasdaq: ORCH ), a ... announced the appointment of William J. Thomas, Esq. ... was formerly Senior Vice President and General Counsel ... the,management of outside general and intellectual property counsel. ...
... 20 Neurobiological,Technologies, Inc. ("NTI") (Nasdaq: NTII ... 19, 2007 by The NASDAQ Stock Market that ... continued listing,standards. Previously, the NASDAQ Listing Qualifications Department ... with the $35 million market,value of listed securities ...
... Cord Blood America, Inc.,(OTC Bulletin Board: CBAI), ... http://www.cordblood-america.com ) focused on bringing the life,saving potential ... today revenues for the first nine months of ... revenues of $2.582 million in the same,period in ...
... Nov. 19 Viant, Inc., a leader in,healthcare ... of Keith Vangeison as Executive Vice President of ... strategy, with a,focus on delivering quality and value ... groups. Mr. Vangeison will have responsibility for ...
Cached Medicine News:Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 2Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 3Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 4Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 5Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 6Health News:CVS/pharmacy Launches St. Jude Thanks and Giving(R) Campaign in Stores Nationwide 2Health News:CVS/pharmacy Launches St. Jude Thanks and Giving(R) Campaign in Stores Nationwide 3Health News:Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel 2Health News:Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel 3Health News:Cord Blood America Revenues Up 121 Percent in First Nine Months of 2007 2Health News:Viant Appoints Keith Vangeison as Executive Vice President of Network Development 2
(Date:12/17/2014)... , December 17, 2014 ... nothing less than a hub of information concerning the biopharmaceutical ... A further addition to the recently launched institutional ... and has now been enriched by a new chapter in ... A richly detailed and panoramic hub on the ...
(Date:12/17/2014)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... in its first Phase 2a study, RXI-109-1301.  The ... 1-month findings that were reported in September of ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... Registreer nu via  http://bit.ly/ag8Sypm14de ... Februar sind alle akkreditierten pharmazeutischen Patientenversorgungsakten-Firmen (PMR) ... PROGRAMM ™ 2015 in Amsterdam ... Tagung soll dazu beitragen, der Aegate PMR ... profitablen Unternehmensdienstleistungen, die für Apotheken und die ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... 2010 AstraZeneca (NYSE: ... it will discontinue the development of CERTRIAD™ (rosuvastatin calcium and ... mixed dyslipidemia. This means the co-development and license agreement with ... A Complete Response Letter (CRL) for the CERTRIAD New Drug ...
... Inc (NYSE: PFE ) today announced that ... States Food and Drug Administration (FDA) and the European ... 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) to ... prevention of pneumococcal disease caused by the 13 serotypes ...
Cached Medicine Technology:Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 2Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 3Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 4Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: